{'fraction_non_alphanumeric': 0.02313624678663239, 'fraction_numerical': 0.012853470437017995, 'mean_word_length': 5.385245901639344, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia

Ibrutinib, the first in class of BTK inhibitor, has improved the management of patients with chronic lymphocytic leukemia. Since ibrutinib can cause atrial fibrillation in 6-16% of cases, it is clinically relevant to identify patients at higher risk to develop atrial fibrillation. Comorbidities associated with a higher risk to develop atrial fibrillation were recapitulated in a scoring system. This model proved to be a valid prognostic tool both in a general chronic lymphocytic leukemia population (n=860) and in an ibrutinib-treated cohort (n=354). Patients with score≥5 harbored the highest risk of atrial fibrillation and should be carefully monitored during ibrutinib therapy.